Literature DB >> 24057464

Follow-up of prenatally diagnosed unilateral hydronephrosis.

J Thorup1, K Lenz, A Rabol, A Passalides, O H Nielsen.   

Abstract

Based on previous experience with prenatally diagnosed unilateral hydronephrosis, we found that the primary indications for surgical intervention should be symptoms or functional impairment of the hydronephrotic kidney. Nonoperative management of neonates without symptoms and with normal function of the affected kidney was proposed. However, the strategy of treatment after prenatally diagnosed hydronephrosis is still controversial. We studied 28 consecutive children with suspected unilateral pelviureteral junction obstruction and a normal contralateral kidney. The overall follow-up period varied between 2.5 months and 6 years (median 2 years). Eleven children had normal function of the hydronephrotic kidney and were managed nonoperatively throughout the follow-up period. None of these demonstrated any symptoms and the renal function remained normal. A further 4 children with normal function of the affected kidney were managed nonoperatively, but later had a pyeloplasty performed because of either symptoms or deterioration of renal function. Eleven children had a pyeloplasty performed after the first renography showed that the hydronephrotic kidney provided less than 40% of total renal function. The age at pyeloplasty was 3 weeks- 7 months (median 6 weeks). In all cases but 1 the function of the affected kidney improved. Two patients with impaired hydronephrotic renal function were not operated upon. Our results indicate no need to change the strategy of treatment.

Entities:  

Year:  1996        PMID: 24057464     DOI: 10.1007/BF00174578

Source DB:  PubMed          Journal:  Pediatr Surg Int        ISSN: 0179-0358            Impact factor:   1.827


  13 in total

1.  Nonoperative management of unilateral neonatal hydronephrosis.

Authors:  S A Koff; K Campbell
Journal:  J Urol       Date:  1992-08       Impact factor: 7.450

2.  Antenatally detected pelviureteric junction obstruction. Is non-operation safe?

Authors:  N P Madden; D F Thomas; A C Gordon; R J Arthur; H C Irving; S E Smith
Journal:  Br J Urol       Date:  1991-09

3.  The postnatal management of hydronephrosis diagnosed by prenatal ultrasound.

Authors:  P G Ransley; H K Dhillon; I Gordon; P G Duffy; M J Dillon; T M Barratt
Journal:  J Urol       Date:  1990-08       Impact factor: 7.450

4.  Management of ureteropelvic junction obstruction in neonate.

Authors:  M A Koyle; R M Ehrlich
Journal:  Urology       Date:  1988-06       Impact factor: 2.649

5.  The prognostic value of probe renography in ureteric stone obstruction.

Authors:  A Holm-Nielsen; T Jørgensen; P Mogensen; J Fogh
Journal:  Br J Urol       Date:  1981-12

6.  Ureteropelvic junction obstruction in the neonate.

Authors:  G T Bernstein; J Mandell; R L Lebowitz; S B Bauer; A H Colodny; A B Retik
Journal:  J Urol       Date:  1988-11       Impact factor: 7.450

Review 7.  Natural history of fetal and neonatal hydronephrosis.

Authors:  L R King; P A Hatcher
Journal:  Urology       Date:  1990-05       Impact factor: 2.649

8.  The case for immediate pyeloplasty in the neonate with ureteropelvic junction obstruction.

Authors:  L R King; P W Coughlin; E C Bloch; J D Bowie; K Ansong; M K Hanna
Journal:  J Urol       Date:  1984-10       Impact factor: 7.450

9.  Diuresis renography and simultaneous renal pelvic pressure in hydronephrosis.

Authors:  E U Poulsen; J Frøkjaer; F Taagehøj-Jensen; T M Jørgensen; J P Nørgaard; M Hedegaard; J C Djurhuus
Journal:  J Urol       Date:  1987-08       Impact factor: 7.450

10.  Hydronephrosis due to pelviureteric junction obstruction in infancy.

Authors:  J Valayer; G Adda
Journal:  Br J Urol       Date:  1982-10
View more
  1 in total

Review 1.  Primary non-surgical management of unilateral ureteropelvic junction obstruction in children: a systematic review.

Authors:  Marcus Weitz; Maria Schmidt; Guido Laube
Journal:  Pediatr Nephrol       Date:  2016-12-23       Impact factor: 3.714

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.